Epigamia: $20 Mn secondary, no fresh capital in
Verlinvest, the Mirchandani family and new entrant Sauce.vc have bought about $20 million of Epigamia shares from existing investors. It is a secondary transaction, so the company itself received no money.
- This is a $20 million secondary transaction, so shares changed hands between investors and Epigamia itself received no new capital.
- Verlinvest, the Mirchandani family and new entrant Sauce.vc bought, while DSG Consumer Partners, KA Enterprises and unspecified existing investors sold.
- The latest filed financials are FY24: operating revenue of Rs 173.7 crore, up 3.3%, and a net loss of Rs 17.4 crore, down 74% from FY23.
- Neither stake percentages nor a deal valuation is stated in the report, so any implied number would be invented rather than sourced.
Verlinvest, the Mirchandani family and Sauce.vc have bought about $20 million worth of Epigamia shares from existing investors, Inc42 reported on 25 August. This is a secondary transaction, and that is the whole point of the story: the shares moved between shareholders and no fresh capital went into the company. Epigamia did not raise $20 million.
The sellers were DSG Consumer Partners, KA Enterprises, the investment firm of Deepika Padukone, and other existing investors who were not specified. Sauce.vc is new to the cap table. Verlinvest and the Mirchandani family, the family of late founder Rohan Mirchandani, added to holdings they already had. Stake percentages before and after the deal are not stated, and no valuation is stated.
Ritesh Gauba, appointed chief executive officer in May 2026, said: “The strengthened commitment from Verlinvest, the Mirchandani family, and the new institutional commitment from Sauce is a strong endorsement of the business we have built and the opportunity ahead”
The financials on record are FY24, and Inc42 states that FY25 accounts are yet to be filed, so in August 2026 the public picture is two years old. FY24 operating revenue was Rs 173.7 crore, up 3.3% from Rs 168.1 crore in FY23. FY24 net loss was Rs 17.4 crore, down 74% from Rs 67 crore in FY23. The shape there is a loss cut by roughly three quarters against revenue that was close to flat. Total capital raised by the company to date is around $60 million.
The operator read is about who wants to own this business for the next stretch. An early consumer fund is selling, a strategic investor and the founding family are buying more, and a new institutional name is coming in. That is a handover of time horizon, not a verdict on the business, and nothing in the report says anything about what Epigamia is worth. If you are building a chilled or short-shelf-life category with the same shape, plan for your earliest backers to want liquidity long before any listing, and expect the buyer of their stock to care more about category position over the long run than about a markup at the next round. Have that conversation with your cap table before someone else starts it for you.
Zane’s analysis draws on original reporting by Inc42. Read the original report.